For insights into the competition among leading pharmaceutical companies and future market trends, refer to the article “GLP-1 Weight Loss Drug Market Analysis: Competition Between Eli Lilly and Novo Nordisk and Future Market Trends.”

Mechanistic Differences Between Traditional and Biased GLP-1RAs

The key difference between conventional GLP-1RAs and next-generation biased GLP-1RAs lies in the selectivity of intracellular signaling pathways activated after receptor binding.

1. Traditional GLP-1RAs: Multi-Pathway Activation

When the GLP-1 receptor is activated by conventional GLP-1RAs, multiple intracellular signaling pathways are simultaneously triggered, including:

● cAMP signaling pathway

● β-arrestin recruitment

Although this “multi-pathway activation” can produce strong short-term pharmacological effects, the involvement of β-arrestin may promote receptor internalization and desensitization, potentially reducing the duration of drug activity.

2. Biased GLP-1RAs: Selective Activation of Key Pathways

The design concept of cAMP-biased GLP-1RAs is to optimize molecular structure in order to preferentially activate the cAMP signaling pathway while reducing β-arrestin recruitment.

The biased GLP-1RA Ecnoglutide, for example, has demonstrated in studies:

● Maximum β-arrestin recruitment of approximately 54%–60%

● Reduced receptor internalization

● Prolonged receptor signaling duration

This mechanistic optimization helps maintain more sustained metabolic regulatory effects.

In animal studies, biased GLP-1RAs have also shown stronger stimulation of insulin secretion and improved glycemic control in diabetic mouse models.

Optimization of Receptor Affinity and Dosing Strategies

With advances in molecular design technologies, next-generation GLP-1 drugs are also improving in terms of receptor binding affinity and molecular stability.

Studies indicate that some biased GLP-1RAs exhibit significantly higher binding affinity to the human GLP-1 receptor, which may enhance signal transduction efficiency and maintain more stable pharmacological effects.

From a pharmacokinetic perspective, structural modifications and molecular stabilization strategies can extend the half-life of certain GLP-1 therapies, supporting long-acting, once-weekly dosing regimens.

For example, pharmacokinetic studies of the biased GLP-1RA Ecnoglutide have shown that its steady-state half-life ranges from approximately 143 to 151 hours, providing the pharmacological basis for a long-acting weekly formulation.

Meanwhile, the development of GLP-1 therapies is also expanding toward oral small-molecule drugs.

For example, Orforglipron (brand name Foundayo), developed by Eli Lilly, has received approval from the U.S. Food and Drug Administration and has been launched as the first non-peptide oral small-molecule GLP-1 receptor agonist approved for weight management.

Clinical studies have shown that this drug produces significant improvements in glycemic control and weight reduction, with the highest dose achieving an average body-weight reduction of approximately 12%, offering a new therapeutic option for patients with obesity and metabolic disorders.

Clinical Evidence: Durable Glycemic Control and Sustained Weight Loss

The advantages suggested by mechanistic studies must ultimately be confirmed through clinical trials. In recent years, multiple Phase III clinical studies have evaluated the efficacy of biased GLP-1RAs.

1. Stable Glycemic Control Over 52 Weeks

In the EECOH-1 study involving patients with type 2 diabetes:

● Baseline HbA1c was approximately 8.5%

● Patients received 0.6 mg or 1.2 mg Ecnoglutide once weekly

After 24 weeks of treatment, results showed:

Mean HbA1c reduction of 1.96%–2.43%

More importantly, this glycemic improvement remained stable through week 52, with no significant loss of efficacy observed.

In another study, EECOH-2, Ecnoglutide combined with metformin also demonstrated superior glucose-lowering efficacy compared with the active control group and maintained stable results throughout the 52-week follow-up period.

2. Significant Weight Loss Over 48 Weeks

Biased GLP-1RAs have also shown promising potential in long-term weight management.

In the large Phase III SLIMMER study conducted in China:

● 2.4 mg Ecnoglutide once weekly

● 48 weeks of treatment

The study results showed:

● Average body-weight reduction of 15.4%

● Continuous downward weight trend

● No clear plateau during treatment

These findings suggest that biased GLP-1RAs may offer strong potential for sustained long-term weight reduction.

Safety and Tolerability

In terms of safety, biased GLP-1RAs have generally demonstrated good tolerability.

The most common adverse events are gastrointestinal-related reactions, including:

● Nausea

● Vomiting

● Diarrhea

● Decreased appetite

These adverse reactions are typically mild to moderate in severity, most commonly occurring during the dose-escalation phase, and often diminish over time as treatment continues.

Clinical studies have shown that the discontinuation rate due to gastrointestinal adverse events is relatively low, and the incidence of serious adverse events is not significantly different from that observed in placebo groups.

Conclusion

Biased GLP-1 receptor agonists represent an important technological advancement over traditional GLP-1RAs by selectively activating the cAMP signaling pathway while reducing β-arrestin recruitment.

This signaling bias design not only enhances receptor affinity but may also prolong drug activity, supporting more sustained glycemic control and weight-loss effects.

With the publication of multiple Phase III clinical trial results, next-generation GLP-1 therapies are demonstrating their potential in the treatment of metabolic diseases and may offer new therapeutic options for the future management of diabetes and obesity.

Global pharmaceutical distributor DengYueMed continues to monitor the development of innovative metabolic disease therapies and is committed to connecting international healthcare partners with high-quality pharmaceutical resources, helping improve access to innovative medicines in global markets.